Global Burden of Female Breast Cancer Attributable to High Fasting Plasma Glucose From 1990 to 2021 and Projections to 2046: An Analysis for the Global Burden of Disease Study 2021

IF 4.6 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes/Metabolism Research and Reviews Pub Date : 2025-07-01 DOI:10.1002/dmrr.70063

Donglin Jiang, Siyao Ma, Yangxue Wu, Jicun Zhu, Qian Yang, Ling Liu, Tiandong Li, Yin Lu, Yuqi Liu, Peng Wang, Keyan Wang, Jianxiang Shi, Hua Ye

{"title":"Global Burden of Female Breast Cancer Attributable to High Fasting Plasma Glucose From 1990 to 2021 and Projections to 2046: An Analysis for the Global Burden of Disease Study 2021","authors":"Donglin Jiang, Siyao Ma, Yangxue Wu, Jicun Zhu, Qian Yang, Ling Liu, Tiandong Li, Yin Lu, Yuqi Liu, Peng Wang, Keyan Wang, Jianxiang Shi, Hua Ye","doi":"10.1002/dmrr.70063","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>High fasting plasma glucose (HFPG) plays an important role in the progression of breast cancer. This study aims to assess the global time trends of female breast cancer attributable to HFPG from 1990 to 2021 and projections to 2046.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study obtained the number and age-standardised rate of deaths and disability-adjusted life years (DALYs) of female breast cancer burden attributable to HFPG by age, region, country, and socio-demographic index (SDI) from 1990 to 2021. Average Annual Percentage Change (AAPC) was analysed to assess time trends in female breast cancer burden attributable to HFPG. The age-period-cohort model was used to project the global burden by 2046.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In 2021, 4.62% of female breast cancer deaths (30,000) and 4.04% of DALYs (820,000) globally were attributed to HFPG. Compared with 1990, the age-standardised mortality rate (ASMR) and age-standardised DALY rate (ASDR) increased, with AAPCs of 0.76 (95% CI: 0.71, 0.89) and 0.86 (95% CI: 0.84, 0.98), respectively. The burden of breast cancer attributable to HFPG was higher in the elderly and low SDI regions. Additionally, the burden of female breast cancer attributable to HFPG is projected to continue to increase through 2046.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The burden of female breast cancer attributable to HFPG has increased over the past three decades and will continue to increase over the next 25 years. Therefore, it is important to control blood sugar to reduce the burden of breast cancer.</p>\n </section>\n </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 5","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70063","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70063","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

High fasting plasma glucose (HFPG) plays an important role in the progression of breast cancer. This study aims to assess the global time trends of female breast cancer attributable to HFPG from 1990 to 2021 and projections to 2046.

Methods

This study obtained the number and age-standardised rate of deaths and disability-adjusted life years (DALYs) of female breast cancer burden attributable to HFPG by age, region, country, and socio-demographic index (SDI) from 1990 to 2021. Average Annual Percentage Change (AAPC) was analysed to assess time trends in female breast cancer burden attributable to HFPG. The age-period-cohort model was used to project the global burden by 2046.

Results

In 2021, 4.62% of female breast cancer deaths (30,000) and 4.04% of DALYs (820,000) globally were attributed to HFPG. Compared with 1990, the age-standardised mortality rate (ASMR) and age-standardised DALY rate (ASDR) increased, with AAPCs of 0.76 (95% CI: 0.71, 0.89) and 0.86 (95% CI: 0.84, 0.98), respectively. The burden of breast cancer attributable to HFPG was higher in the elderly and low SDI regions. Additionally, the burden of female breast cancer attributable to HFPG is projected to continue to increase through 2046.

Conclusions

The burden of female breast cancer attributable to HFPG has increased over the past three decades and will continue to increase over the next 25 years. Therefore, it is important to control blood sugar to reduce the burden of breast cancer.

Abstract Image

查看原文本刊更多论文

1990年至2021年空腹高血糖导致的全球女性乳腺癌负担和到2046年的预测：2021年全球疾病负担研究分析

背景：高空腹血糖（HFPG）在乳腺癌的发展中起重要作用。本研究旨在评估1990年至2021年全球因HFPG导致的女性乳腺癌的时间趋势，并预测到2046年。方法按年龄、地区、国家和社会人口指数（SDI）统计1990 - 2021年因HFPG导致的女性乳腺癌负担的死亡数、年龄标准化死亡率和伤残调整生命年（DALYs）。分析平均年百分比变化（AAPC）以评估归因于HFPG的女性乳腺癌负担的时间趋势。年龄-时期-队列模型用于预测到2046年的全球负担。结果2021年，全球4.62%的女性乳腺癌死亡（3万例）和4.04%的DALYs（82万例）归因于HFPG。与1990年相比，年龄标准化死亡率（ASMR）和年龄标准化DALY （ASDR）增加，AAPCs分别为0.76 （95% CI: 0.71, 0.89）和0.86 （95% CI: 0.84, 0.98）。在老年人和低SDI地区，HFPG导致的乳腺癌负担更高。此外，预计到2046年，由HFPG引起的女性乳腺癌负担将继续增加。结论HFPG导致的女性乳腺癌负担在过去30年有所增加，并将在未来25年继续增加。因此，控制血糖对减轻乳腺癌负担十分重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes/Metabolism Research and Reviews 医学-内分泌学与代谢

CiteScore

17.20

自引率

2.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.